List of Dexilant drug patents

Dexilant is owned by Takeda Pharms Usa.

Dexilant contains Dexlansoprazole.

Dexilant has a total of 18 drug patents out of which 1 drug patent has expired.

Expired drug patents of Dexilant are:

  • US6664276

Dexilant was authorised for market use on 30 January, 2009.

Dexilant is available in capsule, delayed release;oral dosage forms.

Dexilant can be used as use of dexlansoprazole in patients taking clopidogrel without meaningful cyp2c19 interactions, for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal disease (gerd); to maintain healing of ee and relief of heartburn; for healing of all grades of erosive esophagitis (ee), treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; to maintain healing of ee and relief of heartburn; maintain healing of erosive esophagitis (ee) for up to 6 months; healing of all grades of erosive esophagitis (ee) for up to 8 weeks, treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; healing of all grades of erosive esophagitis (ee) for up to 8 weeks; maintain healing of erosive esophagitis (ee) for up to 6 months.

The generics of Dexilant are possible to be released after 05 March, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jan, 2023

(8 days ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6664276

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Jul, 2023

(5 months from now)

US8784885 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(8 months from now)

US8722084 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(8 months from now)

US8722084

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(1 year, 2 months from now)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(1 year, 2 months from now)

US8461187 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(2 years from now)

US9238029 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(2 years from now)

US9011926 TAKEDA PHARMS USA Method for producing granules
Feb, 2026

(3 years from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form
Jul, 2026

(3 years from now)

US7790755 TAKEDA PHARMS USA Controlled release preparation
Aug, 2026

(3 years from now)

US8105626 TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount
Sep, 2026

(3 years from now)

US7790755

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Feb, 2027

(3 years from now)

US8105626

(Pediatric)

TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount
Mar, 2027

(4 years from now)

US8871273 TAKEDA PHARMS USA Method for producing granules
Jan, 2028

(4 years from now)

US8173158 TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food
Mar, 2030

(7 years from now)

US8173158

(Pediatric)

TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food
Sep, 2030

(7 years from now)

US9233103 TAKEDA PHARMS USA Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
Mar, 2032

(9 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: For the treatment of heartburn associated with symptomatic non-erosive gastroesophageal disease (gerd); To maintain healing of ee and relief of heartburn; For healing of all grades of erosive esophagitis (ee); Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Healing of all grades of erosive esophagitis (ee) for up to 8 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months; Use of dexlansoprazole in patients taking clopidogrel without meaningful cyp2c19 interactions

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of DEXILANT before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in